Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches : Episode 4
Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies
Dr Mohan asks Dr Nadeem about the selection process among bispecific antibodies, the factors influencing decision-making, and the use of talquetamab, teclistamab, or elranatamab in specific patient subgroups, followed by a discussion with Dr Mann on next therapeutic steps if a patient experiences disease progression on talquetamab.
Video content above is prompted by the following:
- How do you approach the selection process among the various available bispecific antibodies?
- What key factors influence your decision?
- In which specific patient subgroups would you lean toward using talquetamab, teclistamab, or elranatamab?
- If this patient were to experience disease progression on talquetamab, what would be your next therapeutic approach and why?
- What considerations would guide your decision-making process?
Recent Videos
Related Content
